The startup manufactures nano-scale fluid sampling and testing systems that electrochemically detect blood analytes in interstitial fluid, providing regular clinical-grade readings of blood biomarkers. This technology enables healthcare providers to monitor patient progress and make informed clinical decisions based on accurate biomarker data.
Funding
$24.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for monitoring blood biomarkers often require invasive procedures and laboratory analysis, leading to infrequent measurements and delayed insights into patient health trends. This can hinder timely clinical decision-making and proactive management of chronic conditions.
Solution
Cambridge Medical Technologies develops nano-scale fluid sampling and testing systems designed for continuous, non-invasive monitoring of blood analytes in interstitial fluid. Their electrochemical sensors provide clinical-grade readings of key blood biomarkers in real-time, enabling healthcare providers to track patient progress and make informed decisions based on accurate, trended data. The system accesses subcutaneous interstitial fluid without invasive procedures, offering a more convenient and frequent monitoring solution compared to traditional blood draws. By providing longitudinal patient data, the technology aims to improve the management of specific diseases and treatments through real-time insights into blood chemistry.
Target Audience
The primary target audience includes healthcare providers in relevant medical specialties who require frequent, accurate monitoring of patient blood biomarkers, as well as patients with chronic conditions requiring close monitoring of their health status.
Features
- Non-invasive access to subcutaneous interstitial fluid for analyte monitoring.
- Electrochemical detection of blood analytes at the nano-scale.
- Real-time, clinical-grade readings of blood biomarkers.
- Continuous monitoring capabilities for trended longitudinal data.